Research Paper Volume 14, Issue 12 pp 5131—5152

Exploring immune-related signatures for predicting immunotherapeutic responsiveness, prognosis, and diagnosis of patients with colon cancer

class="figure-viewer-img"

Figure 5. Comparison of the expression levels of the immune checkpoints and their ligands between the high-risk score group and low-risk score group. The expression of PD-1 (A), PD-L1 (B), CTLA-4 (C), HAVCR2 (D), LAG3 (E), or TIGIT (F).